Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H G M Heijerman

Showing results (31-40 of 32) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 32 results.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 12, 2020
Clinical effect of lumacaftor/ivacaftor in F508del homozygous CF patients with FEV<sub>1</sub> ≥ 90% predicted at baselineB L Aalbers, K M de Winter-de Groot, H G M Arets, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 26, 2020
Females with cystic fibrosis have a larger decrease in sweat chloride in response to lumacaftor/ivacaftor compared to malesB L Aalbers, R W Hofland, I Bronsveld, et al.
Pageof 4

Showing results (31-40 of 32) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 32 results.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 12, 2020
Clinical effect of lumacaftor/ivacaftor in F508del homozygous CF patients with FEV<sub>1</sub> ≥ 90% predicted at baselineB L Aalbers, K M de Winter-de Groot, H G M Arets, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 26, 2020
Females with cystic fibrosis have a larger decrease in sweat chloride in response to lumacaftor/ivacaftor compared to malesB L Aalbers, R W Hofland, I Bronsveld, et al.
Pageof 4